Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.
Repligen to Report First Quarter 2025 Financial Results
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
Repligen Appoints Jacob Johnson As Vice President Investor Relations
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.